ChemicalBook
Chinese english Germany Korea

アシクロビル

アシクロビル 化学構造式
59277-89-3
CAS番号.
59277-89-3
化学名:
アシクロビル
别名:
アシクロビル;2-アミノ-9-(2-ヒドロキシエトキシメチル)-6,9-ジヒドロ-1H-プリン-6-オン;ゾビクロビル;アシクリル;ベルクスロン;2-アミノ-9-(2-ヒドロキシエトキシメチル)-9H-プリン-6-オール;アシロベック;2-アミノ-9-(2-ヒドロキシエトキシメチル)-1H-プリン-6(9H)-オン;アシビル;2-アミノ-6,9-ジヒドロ-9-[(2-ヒドロキシエトキシ)メチル]-1H-プリン-6-オン;アクチオス;ゾビラックス;シクロビラン;2-アミノ-9-[(2-ヒドロキシエトキシ)メチル]-9H-プリン-6(1H)-オン;ゾビアトロン;アストリック;アシクロメルク;アシクロビン;グロスパール;アクチダス
英語化学名:
Acyclovir
英語别名:
ACV;ovir;AcycL;Zoviax;bw248u;vipral;Zyclir;Vimrax;aclovir;virorax
CBNumber:
CB7126677
化学式:
C8H11N5O3
分子量:
225.2
MOL File:
59277-89-3.mol

アシクロビル 物理性質

融点 :
256-257°C
沸点 :
366.71°C (rough estimate)
比重(密度) :
1.3654 (rough estimate)
屈折率 :
1.8000 (estimate)
貯蔵温度 :
2-8°C
溶解性:
H2O: 0.7 mg/mL
外見 :
powder
酸解離定数(Pka):
pKa 2.27 (Uncertain);9.25 (Uncertain)
色:
white
水溶解度 :
Soluble in 1M HCl at 50mg/ml. Soluble in water at 0.7mg/ml. Also soluble in DMSO
Merck :
14,146
安定性::
Stable. Incompatible with strong oxidizing agents.
InChIKey:
MKUXAQIIEYXACX-UHFFFAOYSA-N
CAS データベース:
59277-89-3(CAS DataBase Reference)
IARC:
3 (Vol. 76) 2000
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  Xi,Xn
Rフレーズ  36/37/38-40-20/21/22
Sフレーズ  22-24/25-36-26-23
WGK Germany  2
RTECS 番号 UP0791400
国連危険物分類  IRRITANT
HSコード  29335990
有毒物質データの 59277-89-3(Hazardous Substances Data)
毒性 LD50 in mice (mg/kg): >10,000 orally; 1000 i.p. (Schaeffer)
絵表示(GHS)
注意喚起語 Warning
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H320 眼刺激 眼に対する重篤な損傷性/眼刺激 性 2B 警告 P264, P305+P351+P338,P337+P313
注意書き
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。

アシクロビル 価格 もっと(32)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01COBOR-5147 アシクロビル
Acyclovir
59277-89-3 1g ¥3600 2021-03-23 購入
富士フイルム和光純薬株式会社(wako) W01APOOR9240T アシクロビル
Acyclovir
59277-89-3 100mg ¥28800 2021-03-23 購入
東京化成工業 A1915 アシクロビル >98.0%(HPLC)
Acyclovir >98.0%(HPLC)
59277-89-3 1g ¥1900 2021-03-23 購入
東京化成工業 A1915 アシクロビル >98.0%(HPLC)
Acyclovir >98.0%(HPLC)
59277-89-3 5g ¥5300 2021-03-23 購入
Sigma-Aldrich Japan Y0001264 European Pharmacopoeia (EP) Reference Standard
European Pharmacopoeia (EP) Reference Standard
59277-89-3 ¥35200 2021-03-23 購入

アシクロビル 化学特性,用途語,生産方法

外観

白色~うすい黄色, 結晶~粉末

溶解性

本品0.1gに0.1mol/l水酸化ナトリウム溶液10mlでほとんど澄明

解説

抗ウイルス剤の一。単純ヘルペスウイルスおよび、水痘・帯状疱疹(ほうしん)ウイルスによる単純疱疹・水痘・帯状疱疹、脳炎・髄膜炎の治療薬。
小学館 デジタル大辞泉について 情報 | 凡例

用途

ウイルス DNA ポリメラーゼ / 逆転写酵素による基質の取り込みを競合的 に阻害し、DNA 鎖の伸長を停止することによ りウイルス増殖阻害作用を示します。

用途

ウイルス感染症の治療薬である。単純ヘルペスウイルスや水痘?帯状疱疹ウイルスに使われる。グラクソ?スミスクラインよりゾビラックス、一般薬としてヘルペシア、後発医薬品も多数。

効能

抗ウイルス薬, DNAポリメラーゼ阻害薬

商品名

アシクロビル (東亜薬品); ゾビラックス (グラクソ・スミスクライン); ゾビラックス (グラクソ・スミスクライン); ゾビラックス (グラクソ・スミスクライン); ゾビラックス (グラクソ・スミスクライン); ゾビラックス (グラクソ・スミスクライン); ゾビラックス (日東メディック); ゾビラックス (日東メディック); ビルレクス (日本点眼薬研究所)

説明

As it is evident from the chemical structure, acyclovir looks like a nucleoside analog of guanosine in side chain of which, instead of the traditional cyclic sugar residue a 2-hydroxyethoxymethyl acyclic side chain is present. Acyclovir possesses antiviral activity with respect to types 1 and 2 of herpes simplex, shingles virus, Epstein–Barr virus, and cytomegalovirus.

化学的特性

white to light yellow crystal powder

使用

Orally active acyclic nucleoside with inhibitory activity towards several herpes viruses. Antiviral; hypnotic.

使用

Acyclovir (Zovirax) is a synthetic purine analog derived from guanine. It exerts its effects on the herpes simplex virus (HSV) and varicella-zoster virus by interfering with DNA synthesis through phosphorylation by viral thymidine kinase and subsequent inhibition of viral DNA polymerase, thereby inhibiting viral replication. It is effective against HSV-1 and 2, varicella-zoster virus, Epstein-Barr virus, herpesvirus simiae, and cytomegalovirus. Acyclovir may be administered intravenously, orally, or topically.
Acyclovir Ointment

使用

Inhibits cytomegalovirus replication; induces apoptosis

適応症

Acyclovir (Zovirax) is a synthetic purine analog derived from guanine. It exerts its effects on the herpes simplex virus (HSV) and varicella-zoster virus by interfering with DNA synthesis through phosphorylation by viral thymidine kinase and subsequent inhibition of viral DNA polymerase, thereby inhibiting viral replication. It is effective against HSV-1 and 2, varicella-zoster virus, Epstein-Barr virus, herpesvirus simiae, and cytomegalovirus. Acyclovir may be administered intravenously, orally, or topically.
Acyclovir (400 mg PO b.i.d. or 200 mg PO five times a day) or other antiviral antibiotics can suppress herpes-associated EM. It is of no value once the EM has started. Not all episodes of a herpes simplex recurrence are associated with EM, but in recurrent cases, a 6-month trial of suppressive therapy can be helpful.

定義

ChEBI: An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9.

Manufacturing Process

Solid sodium nitrite (0.97 g) was added at room temperature with stirring over a period of one hour to a solution of 2-chloro-9-(2- hydroxyethoxymethyl)adenine (0.5 g) in glacial acetic acid (10 ml). The reaction mixture was stirred for an additional 4? hours. The white solid was removed by filtration, washed with cold acetic acid and then well triturated with cold water to remove the sodium acetate present. The solid product was retained. The combined acetic acid filtrate and wash was evaporated at reduced pressure and 40°C bath temperature and the residual oil triturated with cold water. The resulting solid material was combined with the previously isolated solid and the combined solids dried and recrystallized from ethanol to give 2-chloro-9-(2-hydroxyethoxymethyl)-hypoxanthine (0.25 g), MP>310°C. Elemental analysis and NMR spectrum were consistent with this structure.
A mixture of 2-chloro-9-(2-hydroxyethoxymethyl)-hypoxanthine (0.375 g) and methanol (80 ml) saturated with anhydrous ammonia was heated in a bomb at 125°C for 5 hours. The bomb was cooled in an ice bath and the reaction mixture removed. Solvent and excess ammonia were removed under reduced pressure at 50°C. After the residue was triturated with cold water to remove the ammonium chloride formed, the remaining solid was dried and then recrystallized from methanol to give pure 9-(2-hydroxyethoxymethyl) guanine (0.24 g), MP 256.5-257°C.

brand name

Zovirax (GlaxoSmithKline).

Therapeutic Function

Antiviral

抗菌性

Activity is restricted to viruses of the herpes group. Herpes simplex virus (HSV) types 1 and 2, simian herpes virus B and varicella zoster viruses (VZV) are susceptible to concentrations readily attainable in human plasma. The 50% inhibitory concentration (ID50) is 0.1 μmol for HSV-1 and HSV-2 and 3 μmol for VZV, concentrations much below those toxic to cells. Valaciclovir is metabolized to aciclovir, and has the same antiviral profile. Thymidine-kinase-negative HSV mutants and cytomegalovirus (CMV) do not code for thymidine kinase and are generally resistant. Although Epstein–Barr virus (EBV) may have reduced thymidine kinase activity, its DNA polymerase is susceptible to aciclovir triphosphate and shows intermediate susceptibility. Human herpes viruses 6 and 7 are less susceptible than EBV.

獲得抵抗性

Mutations in HSV that involve deficient thymidine kinase or an altered substrate are most common; alterations in the DNA polymerase gene also result in resistance. Resistant mutants may be found in wild virus populations; mutants lacking thymidine kinase activity may be readily induced by passage of HSV in the presence of the drug. Resistant strains have mostly been reported in immunocompromised patients, are generally thymidine-kinase negative, and have decreased virulence. Resistant mutants that retain thymidine kinase activity appear to retain virulence. Emergence of resistant HSV strains is less frequent in immunocompetent patients, occurring in about 2% of those receiving prolonged treatment.

一般的な説明

Acyclovir, 9-[2-(hydroxyethoxy)methyl]-9H-guanine (Zovirax),is the most effective of a series of acyclic nucleosidesthat possess antiviral activity. In contrast with true nucleosidesthat have a ribose or a deoxyribose sugar attached to apurine or a pyrimidine base, the group attached to the basein acyclovir is similar to an open chain sugar, albeit lackingin hydroxyl groups. The clinically useful antiviral spectrumof acyclovir is limited to herpesviruses. It is most active (invitro) against HSV type 1, about two times less against HSVtype 2, and 10 times less potent against varicella–zostervirus (VZV).
The ultimate effect of acyclovir is the inhibition of viralDNA synthesis. Transport into the cell and monophosphorylationare accomplished by a thymidine kinase that is encodedby the virus itself.The affinity of acyclovir for the viralthymidine kinase is about 200 times that of the correspondingmammalian enzyme.
use: oral and parenteral. Oral acyclovir is used in the initialtreatment of genital herpes and to control mild recurrentepisodes. It has been approved for short-term treatment ofshingles and chickenpox caused by VZV. Intravenous administrationis indicated for initial and recurrent infectionsin immunocompromised patients and for the prevention andtreatment of severe episodes. The drug is absorbed slowlyand incompletely from the GI tract, and its oral bioavailabilityis only 15% to 30%. Nevertheless, acyclovir is distributedto virtually all body compartments.

応用例(製薬)

A synthetic acyclic purine nucleoside analog of the natural nucleoside 2′ deoxyguanosine, formulated for oral and topical use, and as the sodium salt for intravenous infusion. Valaciclovir (the l-valyl ester) is a prodrug formulation supplied as the hydrochloride for oral use.

生物活性

Antiviral agent, active against herpes simplex viruses HSV-1 and HSV-2 (EC 50 values are 0.85 and 0.86 μ M respectively). Interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate. Induces apoptosis in cells transfected with HSV-TK (suicidal gene therapy).

作用機序

Acyclovir is a synthetic analogue of deoxyguanosine in which the carbohydrate moiety is acyclic. Because of this difference in structure as compared to other antiviral compounds (idoxuridine, vidarabine, and trifluridine), acyclovir possesses a unique mechanism of antiviral activity. The mode of action of acyclovir consists of three consecutive mechanisms. The first of these mechanisms involves conversion of the drug to active acyclovir monophosphate within cells by viral thymidine kinase. This phosphorylation reaction occurs faster within cells infected by herpesvirus than in normal cells, because acyclovir is a poor substrate for the normal cell thymidine kinase. Acyclovir is further converted to di- and triphosphates by a normal cellular enzyme called guanosine monophosphate kinase. In the second mechanism, viral DNA polymerase is competitively inhibited by acyclovir triphosphate with a lower median inhibition concentration (IC50) than that for cellular DNA polymerase. Acyclovir triphosphate is incorporated into the viral DNA chain during DNA synthesis. Because acyclovir triphosphate lacks the 3′-hydroxyl group of a cyclic sugar, it terminates further elongation of the DNA chain. The third mechanism depends on preferential uptake of acyclovir by herpes-infected cells as compared to uninfected cells, resulting in a higher concentration of acyclovir triphosphate and leading to a high therapeutic index between herpes-infected cells compared to normal cells. Acyclovir is active against certain herpesvirus infections. These viruses induce virus-specific thymidine kinase and DNA polymerase, which are inhibited by acyclovir. Thus, acyclovir significantly reduces DNA synthesis in virus-infected cells without significantly disturbing the active replication of uninfected cells.

薬物動態学

Oral absorption, aciclovir: c. 20%
valaciclovir: c. 60%
Cmax 200 mg oral 4-hourly:1.4–4 μmol after 1.5–1.75 h
5 mg/kg 8-hourly intravenous infusion: 43.2 μmol steady state
10 mg/kg 8-hourly intravenous infusion: 88.9 μmol steady state
Plasma half-life: 3–3.3 h
Plasma protein binding: 15%
Absorption
Therapeutic drug levels are readily attained after oral or intravenous administration, although concentrations achieved by an oral dose are over 90% lower than those after intravenous therapy. Accumulation of the drug is unlikely in patients without renal dysfunction. Valaciclovir is readily absorbed and is converted rapidly and almost completely to aciclovir; absorption is unaffected by food. Peak plasma concentrations of 22 μmol are found in subjects after an oral dose of 1000 mg every 8 h; systemic exposure is comparable to that of intravenous aciclovir 5 mg/kg every 8 h. The peak plasma concentration and area under the concentration–time curve (AUC) do not increase proportionally with increasing doses, presumably due to reduced absorption. The time to peak aciclovir concentration is also dose dependent, ranging from 0.9 to 1.8 h after single oral doses of 100–1000 mg.
Distribution
Aciclovir is widely distributed in various tissues and body fluids. Delivery of the drug to the basal epidermis after topical administration is about 30–50% of that obtained by oral dosing. Aciclovir ointment penetrates the corneal epithelium. CSF concentrations are about 50% of simultaneous plasma concentrations. Vesicular fluid concentrations approximate those in plasma. The drug is actively secreted into breast milk at a concentration several times that of plasma. Placental cord blood contains levels of 69–99% of maternal plasma and the drug is 3–6 times more concentrated in amniotic fluid.
Metabolism
About 15% of an intravenous dose is metabolized in persons with normal renal function. The only significant urinary metabolite is 9-carboxymethoxymethylguanine, which has no antiviral activity. Less than 0.2% of the dose is recovered as the 8-hydroxylation product.
Excretion
Around 45–79% of a dose is recovered unchanged in urine, the percentage declining with decreasing creatinine clearance. In patients with renal failure, mean peak plasma concentrations nearly doubled and the elimination half-life increased to 19.5 h. Dosage reductions are advised for various stages of renal impairment. During hemodialysis the half-life is 5.7 h and after dialysis the plasma concentration is about 60% less than the predialysis concentration. Half-lives of 12–17 h have been reported for patients undergoing continuous peritoneal dialysis, with only 13% or less of administered drug being recovered in the 24-h dialysate. The half-life in patients undergoing arteriovenous hemofiltration/dialysis is about 20 h. Less than 1% of a dose of valaciclovir is recovered as unchanged drug in the urine. In multidose studies the amount of aciclovir recovered across dose levels ranged from about 40% to 50%. Between 7% and 12% of the dose is found as the 9-carboxymethoxymethylguanine metabolite. Overall, aciclovir accounts for 80–85% of total urinary recovery.

臨床応用

Aciclovir
Herpes simplex keratitis
Chickenpox and herpes zoster
Herpes simplex encephalitis and neonatal herpes
Prophylaxis of HSV infections in the severely immunocompromised
Valaciclovir
Herpes zoster and genital HSV infections

副作用

Few adverse reactions to topical, ocular, oral or intravenous formulations have been reported. Allergic contact dermatitis occasionally occurs with aciclovir cream. Superficial punctate keratopathy occurs in 10% of patients receiving the ophthalmic preparation; stinging or burning on application occurs in 4%. Less common complications include conjunctivitis, blepharitis and pain.
Transient increases in blood urea nitrogen and creatinine occur in 10% of patients given bolus injections. It can be largely avoided by reducing the rate of infusion, adequate hydration and dosage adjustment in renal failure. Nausea, vomiting, diarrhea and abdominal pain occasionally occur, particularly in association with a raised creatinine concentration. Acute reversible renal failure has been reported. Reconstituted aciclovir has a pH of about 11; severe inflammation and ulceration have been reported after extravasation at the infusion site. Encephalopathy, tremors, confusion, hallucinations, convulsions, psychiatric disorders, bone marrow depression and abnormal liver function have occasionally arisen. Skin rashes have been reported in a few patients but resolve on discontinuation of the drug.
Headache and nausea have been reported as side effects of valaciclovir, but occurred with similar frequency in subjects taking placebo.
Results of mutagenicity tests in vitro and in vivo indicate that aciclovir is unlikely to pose a genetic risk to humans, and the drug was not found to be carcinogenic in long-term studies in mice and rats. No detectable drug-related effects have been detected in pregnancy.

Chemical Synthesis

Acyclovir, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one (36.1.5), is synthesized by alkylating guanine with 1-benzoyloxy-2-chloromethoxyethane in triethylamine. The hydroxyl and amino groups of guanine are previously protected with a trimethylsilyl group by being treated with hexamethyldisilazane. After hydrolysis the resulting product with water, 9-(2-benzoyloxymethoxymethyl)guanine (36.1.4) is isolated. Treating this with a methanol solution of ammonia removes the benzoyl protecting group from the hydroxyethoxymethyl fragment, giving acyclovir.

Another way of preparing acyclovir begins with 2,6-dichloropurine, which is alkylated with the same 1-benzoyloxy-2-chloromethoxyethane, but in a triethylamine—dimethylformamide system to make 2,6-dichloro-9-(2-benzoyloxyethoxymethyl)purine (36.1.6). Treating this with a methanol solution of ammonia replaces both chlorine atoms with amino groups, and subsequent diazotization using sodium nitrite in dilute acetic acid selectively replaces one of the two amino groups for a hydroxyl group, in particular the amino group at position C6 of the purine system. Finally, treating the product with a methanol solution of ammonia removes the benzoyl protection from the synthesized 9-(2-benzoyloxyethoxymethyl)guanine (36.1.4) to make acyclovir.

Veterinary Drugs and Treatments

Acyclovir may be useful in treating herpes infections in a variety of avian species and in cats with corneal or conjunctival herpes infections. Its use in veterinary medicine is not well established, however, and it should be used with caution. Acyclovir has relatively mild activity against Feline Herpesvirus-1 when compared to some of the newer antiviral agents (e.g., ganciclovir, cidofovir, or penciclovir).
Acyclovir is being investigated as a treatment for equine herpes virus type-1 myeloencephalopathy in horses, but clinical efficacy has not yet been proven and the drug’s poor oral bioavailability is problematic. There continues to be interest in finding a dosing regimen that can achieve therapeutic levels and be economically viable, particularly since the drug’s use during a recent outbreak appeared to have some efficacy in reducing morbidity and mortality (not statistically proven). Also, intravenous acyclovir may be economically feasible to treat some neonatal foals.

アシクロビル 上流と下流の製品情報

原材料

準備製品


アシクロビル 生産企業

Global( 570)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Zhengzhou Yuanli Biological Technology Co., Ltd
0086-371-67897895
info@zzyuanli.cn CHINA 136 58
APOLLO HEALTHCARE RESOURCES
+6596580999
sales@apollo-healthcare.com.sg Singapore 312 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 sales@capotchem.com China 20012 60
Henan DaKen Chemical CO.,LTD.
+86-371-66670886
info@dakenchem.com China 15427 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com China 22607 55
Hangzhou FandaChem Co.,Ltd.
008615858145714
+86-571-56059825 fandachem@gmail.com CHINA 9134 55
Guangzhou PI PI Biotech Inc
+8618371201331
020-81716319 sales@pipitech.com;87478684@qq.com China 3283 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 739 60
Hubei XinRunde Chemical Co., Ltd.
+8615102730682
02783214688 bruce@xrdchem.cn CHINA 567 55
Hefei TNJ Chemical Industry Co.,Ltd.
+86-0551-65418679
86-0551-65418697 info@tnjchem.com China 3000 55

59277-89-3(アシクロビル)キーワード:


  • 59277-89-3
  • 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-6h-purin-6-on
  • 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)-methyl)-6h-purin-6-on
  • aciclovirum(latin)
  • acielovir
  • cycloguanosine
  • Zoviax
  • 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6h-purin-6-one
  • 2-AMINO-9-(2-HYDROXY-ETHOXYMETHYL)-1,9-DIHYDRO-PURIN-6-ONE
  • ACYCLOVIR SUBST
  • ACYCLOVIR
  • ACYCLOGUANOSINE
  • ACV
  • ACICLOVIR
  • AKOS NCG1-0055
  • A Silowe
  • Aciclovir for system suitability
  • Aciclovir for peak identification 2
  • Aciclovir for peak identification 1
  • Acyclovir Micronized USP37
  • Valaciclovir EP Impurity B
  • Acyclovir solution,100ppm
  • 9-[(2-Hydroxyethoxy)methyl]-1,9-dihydro-2-amino-6H-purin-6-one
  • Zovirax cream
  • 9-[(2-Hydroxyethoxy)methyl]guanine
  • Acycloguanosine,9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir
  • Acyclovir (300 mg)
  • Acycloguanosine/Acyclovir
  • Acyclovir (also product ID A1096)
  • Aciclovir COS
  • Acyclovir API
  • アシクロビル
  • 2-アミノ-9-(2-ヒドロキシエトキシメチル)-6,9-ジヒドロ-1H-プリン-6-オン
  • ゾビクロビル
  • アシクリル
  • ベルクスロン
  • 2-アミノ-9-(2-ヒドロキシエトキシメチル)-9H-プリン-6-オール
  • アシロベック
  • 2-アミノ-9-(2-ヒドロキシエトキシメチル)-1H-プリン-6(9H)-オン
  • アシビル
  • 2-アミノ-6,9-ジヒドロ-9-[(2-ヒドロキシエトキシ)メチル]-1H-プリン-6-オン
  • アクチオス
  • ゾビラックス
  • シクロビラン
  • 2-アミノ-9-[(2-ヒドロキシエトキシ)メチル]-9H-プリン-6(1H)-オン
  • ゾビアトロン
  • アストリック
  • アシクロメルク
  • アシクロビン
  • グロスパール
  • アクチダス
  • クロベート
  • ビクロックス
  • ビルレクス
  • ゾビスタット
  • 9-(2-ヒドロキシエトキシメチル)グアニン
  • 2-アミノ-9-(2-ヒドロキシエトキシメチル)-9H-プリン-6(1H)-オン
  • エアーナース
  • アシクログアノシン
  • アシクロフタル
  • アシロベック-DS
  • ナタジール
  • 2-アミノ-1,9-ジヒドロ-9-[(2-ヒドロキシエトキシ)メチル]-6H-プリン-6-オン
  • ビルヘキサル
  • アシロミン
  • アイラックス
  • ビゾクロス
  • ファルラックス
  • トミール
  • 9-[(2-ヒドロキシエトキシ)メチル]-1,9-ジヒドロ-2-アミノ-6H-プリン-6-オン
  • 2-アミノ-9-(2-ヒドロキシエトキシメチル)-1,6-ジヒドロ-9H-プリン-6-オン
  • 9-[(2-ヒドロキシエトキシ)メチル]グアニン
  • アシクロビル錠
  • アシクロビル顆粒
  • アシクロビル眼軟膏
  • アシクロビル (JP17)
  • アシクロビル錠 (JP17)
  • アシクロビル顆粒 (JP17)
  • アシクロビル眼軟膏 (JP17)
  • ヌクレオシド,ヌクレオチド&関連試薬
  • ヌクレオシドと類似体
  • 生化学
  • 試験研究用抗ウィルス剤
  • 試験研究用抗菌剤
  • 薬理研究用試薬
  • 抗ウイルス薬
  • 眼科用薬
Copyright 2017 © ChemicalBook. All rights reserved